Avidity Partners Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Avidity Partners Management’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,764,100	Closed	-$3.21M	–	110
2023 Q1	$3.21M	Sell	1,764,100 -31,700	-2%	-$51.5K	0.11%	76
2022 Q4	$2.96M	Sell	1,795,800 -10,400	-0.6%	-$16.7K	0.06%	73
2022 Q3	$3.47M	Sell	1,806,200 -43,800	-2%	-$114K	0.07%	84
2022 Q2	$5.53M	Hold	1,850,000	–	–	0.13%	56
2022 Q1	$6.97M	Buy	1,850,000 +462	+0%	+$2.63K	0.15%	66
2021 Q4	$21M	Buy	1,849,538 +166,097	+10%	+$2.53M	0.45%	56
2021 Q3	$29.5M	Sell	1,683,441 -124,953	-7%	-$2.34M	0.65%	50
2021 Q2	$38.7M	Buy	+1,808,394	New	+$33.9M	1.05%	36

Other funds holding CYT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

Avidity Partners Management's CYT Position: Q2 2023 in Review

Avidity Partners Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2023, closing a stake of 1,764,100 shares — an estimated $3.21M sold.

Avidity Partners Management first reported a position in CYT in Q2 2021 and held it in 8 quarters. The position peaked at $38.7M in Q2 2021. 39 funds tracked by Wall St. Rank hold CYT as of Q2 2023.

Avidity Partners Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Avidity Partners Management sold 1,764,100 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.21M.
Avidity Partners Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Avidity Partners Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $38.7M in Q2 2021.
39 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.